Can't wait to see the results. Efficacy across several patients would be amazing but happy as long as no signs of dose limiting toxicities are present.
Also, not sure if its a typo or when the plan was changed (probably an older figure), on Chimerics website under pipeline, the CHM 1101 dosing schema states 220 x 10^6 as the third dose, rather than 240 x 10^6 described here and in the annual report.
Anyone have any idea when they increased the dosage of the third cohort or if its just a type?
Can't wait to see the results. Efficacy across several patients...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $28.14K | 7.037M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 243067 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 14771167 | 22 |
View Market Depth
| Last trade - 15.39pm 20/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |